KEAP1 and non-small cell lung carcinoma: Poor OS was observed in KEAP1-mutated vs. WT NSCLC pateints.Durvalumab alone: 7.6 vs. 14.6 months; Durvalumab + Tremelilumab: 9.2 vs. 11.3 months; Chemotherapy: 6.3 vs. 13.3 months.